Daptomycin
- Atc Codes:J01XX09
- CAS Codes:103060-53-3
- PHARMGKB ID:103060-53-3
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Cubicin; Cyprus: Cubicin; Czech Republic: Cubicin; Denmark: Cubicin; Estonia: Cubicin; Finland: Cubicin; France: Cubicin; Germany: Cubicin; Greece: Cubicin; Hungary: Cubicin; Ireland: Cubicin; Italy: Cubicin; Latvia: Cubicin; Lithuania: Cubicin; Netherlands: Cubicin; Poland: Cubicin; Portugal: Cubicin; Romania: Cubicin; Slovakia: Cubicin; Spain: Cubicin; Sweden: Cubicin; UK: Cubicin.
North America
Canada: Cubicin; USA: Cubicin.
Latin America
Argentina: Cubicin.
Drug combinations
Chemistry
Daptomycin: C~72~H~101~N~17~O~26~. Mw: 1620.67. N-Decanoyl-L-tryptophyl-L-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-threo-3-methyl-L-glutamyl-3-anthraniloyl-L-alanine ε~1~-lactone. CAS-103060-53-3 (1989).
Pharmacologic Category
Antibacterials; Cyclic Lipopeptides. (ATC-Code: J01XX09).
Mechanism of action
Binds to components of the cell membrane of susceptible organisms and causes rapid depolarization, inhibiting intracellular synthesis of DNA, RNA, and protein. Daptomycin is bactericidal in a concentration-dependent manner.
Therapeutic use
Treatment of complicated skin and skin structure infections caused by susceptible aerobic Gram-positive organisms including S. aureus (methicillin-sensitive S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA)), S. pyogenes, S. agalactiae, S. dysgalactiae, and E. faecalis. Treatment of S. aureus bacteremia, including right-sided infective endocarditis caused by MSSA or MRSA.
Pregnancy and lactiation implications
There are no adequate, well-controlled studies in pregnant women. Caution if administered during pregnancy or lactation.
Unlabeled use
Treatment of severe infections caused by MRSA or vancomycin-resistant enterococcus.
Contraindications
Hypersensitivity to daptomycin or any component of the formulation.
Warnings and precautions
Increased incidence of myopathy (use caution in patients receiving other drugs associated with myopathy (e.g. HMG-CoA reductase inhibitors)). Symptoms suggestive of peripheral neuropathy (decreases in nerve conduction velocity and adverse effects (e.g. paresthesias, Bell’s palsy)), may be developed. Prolonged use may result in fungal or bacterial superinfection, including C. difficile-associated diarrhea and pseudomembranous colitis. Use with caution in renal impairment. Should not be used in the treatment of pneumonia (due to poor lung penetration).